NOTE 8 - RELATED PARTY TRANSACTIONS (Details) - USD ($)																										3 Months Ended						9 Months Ended		12 Months Ended
		Jul. 01, 2019	Oct. 19, 2018	May 07, 2018	Apr. 19, 2018	Oct. 02, 2017	Aug. 07, 2017	Apr. 03, 2017	Apr. 01, 2017	Mar. 09, 2017	Mar. 03, 2017	Mar. 01, 2017	Oct. 06, 2016	May 01, 2016	Apr. 07, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2013	Jun. 15, 2019	Dec. 31, 2018	Sep. 06, 2016	Dec. 31, 2015	Feb. 28, 2013	Feb. 29, 2012
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current																										$ 374,901						$ 374,901				$ 234,901
Debt Instrument, Face Amount																																			$ 500,000
Class of Warrant or Rights, Granted (in Shares)																																0
Debt Instrument, Interest Rate, Stated Percentage																																			5.25%
Preferred Stock, Shares Authorized (in Shares)																										20,000,000						20,000,000				20,000,000		20,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)												20,000,000				34,522
Stock Issued During Period, Value, Other																										$ 34,013	$ 89,220	$ 188,961	$ 53,889	$ 204,497	$ 147,713
Debt Conversion, Original Debt, Amount																$ 100,000
Notes Payable, Related Parties																										2,317,365						$ 2,317,365				$ 1,731,104
Repayments of Notes Payable																																381,000	$ 484,381
Repayments of Related Party Debt																																213,739	542,971
Accounts Payable, Related Parties, Current																										3,167						3,167				75,714
Sale Leaseback Transaction, Net Book Value											$ 400,000
Sale Leaseback Transaction, Lease Terms											leased back the sold equipment over a three-year term
Percentage of Renenue Accrued for Marketing											10.00%
Accrued Marketing Costs, Current																										$ 2,378						$ 2,378				$ 179,353
Sale Leaseback Transaction, Description											Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer.  There is no reduction in the selling price should the new customers be fewer than 5,000.  The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction
Proceeds from Sale of Machinery and Equipment											$ 50,000
Northstar Claims [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Percentage of Revenues to be Received as Royalty												10.00%
Stockholders' Equity, Other Shares (in Shares)												11,000,000
Number of Directors												2
Equity Method Investment, Ownership Percentage												5.00%
Northstar Claims [Member] | Stock Issued for Conversion of Series A Preferred Stock and Litigation Case [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)									1,000,000	30,000,000
GACP Stem Cell Bank, LLC [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Investment Agreement, Value								$ 5,000,000
Investment Agreement, Number of Shares (in Shares)								63,873,275
Proceeds from Issuance or Sale of Equity								$ 250,000
Stock Issued During Period, Shares, New Issues (in Shares)								858,281
Shares Held by Affiliate (in Shares)																										4,021,945						4,021,945				4,021,945
Affiliated Entity [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction														The agreement is for 12 months and renewable for 6-month periods.  Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock
Professional Fees																																$ 0	$ 90,000
Accounts Payable, Related Parties, Current																										$ 0						0				$ 64,909
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																								$ 544,267
Debt Instrument, Payment Terms																							Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																								5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																							entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
Percentage of Revenues to be Received as Royalty																							8.00%
Debt Instrument, Interest Rate, Stated Percentage																							12.85%																7.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			164,523		379,141	559,187			286,315												3,916	8,772
Debt Conversion, Original Debt, Amount			$ 9,195		$ 9,145	$ 12,705			$ 12,703												$ 85,447	$ 100,000
Notes Payable, Related Parties																										262,000						262,000				262,000
Affiliated Entity [Member] | Interest [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)													848,490		57,778		4,156	1,363	515	275
Debt Conversion, Original Debt, Amount													$ 12,705				$ 12,705	$ 12,635	$ 12,705	$ 12,635
Debt Conversion, Converted Instrument, Amount															$ 12,705
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																										375,053						375,053				340,009
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #5 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 500,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Notes Payable, Related Parties																										161,786						161,786				483,393
Debt Instrument, Term							1 year
Repayments of Notes Payable																																321,607
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #6 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount				$ 500,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Notes Payable, Related Parties																										500,000	$ 500,000					500,000				500,000
Debt Instrument, Term				6 months
Chief Executive Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #7 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount		$ 500,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Notes Payable, Related Parties																										500,000						500,000				0
Debt Instrument, Maturity Date		Nov. 07, 2019
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																										136,144						136,144				102,974
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #5 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount		$ 300,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Notes Payable, Related Parties	[1]																									300,000						300,000				0
Debt Instrument, Maturity Date		Nov. 07, 2019
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #2 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																					$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																																					5.00%
Notes Payable, Related Parties	[1]																									255,579						255,579				147,711
Repayments of Related Party Debt																																107,868
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #3 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Notes Payable, Related Parties	[1]																									300,000						300,000				300,000
Debt Instrument, Term							1 year
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member] | Note Payable #4 [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount				$ 300,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Notes Payable, Related Parties	[1]																									$ 300,000						$ 300,000				$ 300,000
Debt Instrument, Term				6 months
Series A Preferred Stock [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																							modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Series A Preferred Stock [Member] | Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Value, Other																																		$ 316,800

[1] Dr. Comella is no longer a member of the Board of Directors after September 1, 2019.